Apnimed Past Earnings Performance

Past criteria checks 3/6

Apnimed has been growing earnings at an average annual rate of 18.9%, while the Pharmaceuticals industry saw earnings growing at 10.7% annually. Revenues have been growing at an average rate of 674.1% per year.

Key information

18.92%

Earnings growth rate

33.73%

EPS growth rate

Pharmaceuticals Industry Growth	5.95%
Revenue growth rate	674.09%
Return on equity	n/a
Net Margin	32.46%
Last Earnings Update	31 Mar 2026

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How Apnimed makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGM:APMD Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
31 Mar 26	120	39	25	47
31 Dec 25	38	-58	23	62
31 Dec 24	8	-109	22	97
31 Dec 23	0	-80	11	37
31 Dec 22	1	-26	7	21

Quality Earnings: APMD has high quality earnings.

Growing Profit Margin: APMD became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: APMD has become profitable over the past 5 years, growing earnings by 18.9% per year.

Accelerating Growth: APMD has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: APMD has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-6%).

Return on Equity

High ROE: APMD's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/07/31 10:19
End of Day Share Price	2026/07/30 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Apnimed, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.